undamentalytics Newsletter
Sign in

Camp4 Therapeutics Corp income statement

In fiscal 2025, Camp4 Therapeutics Corp reported revenue of $3.5m, up 436.5% on the year before, operating income of −$52.6m (a -1502.4% margin) and net income of −$80.4m, or −$2.65 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0134
Research and development41393839
General and administrative12151718
Operating income−52−53−53−53
Income tax0000
Net income−49−52−80−107
Diluted EPS−$124.80−$11.04−$2.65—
Diluted shares (average)—5m30m—
EBITDA−50−51−51−51

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CAMP vs CRISCAMP vs ENSCCAMP vs OCGNCAMP vs DBVT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Camp4 Therapeutics Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Camp4 Therapeutics Corp.